Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
26°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Esperion Theraptc
(NQ:
ESPR
)
3.830
+0.350 (+10.06%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 9, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Esperion Theraptc
< Previous
1
2
3
4
5
6
7
8
Next >
Netflix To Rally Around 32%? Here Are 10 Other Analyst Forecasts For Thursday
March 16, 2023
Keybanc cut the price target for LyondellBasell Industries N.V. (NYSE: LYB) from $85 to $74. Keybanc analyst Aleksey Yefremov maintained an Underweight rating. LyondellBasell shares fell 3.7% to close...
Via
Benzinga
Why UiPath Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
March 16, 2023
Gainers ThermoGenesis Holdings, Inc. (NASDAQ: THMO) rose 38.9% to $5.82 in pre-market trading. ThermoGenesis shares jumped around 99% on Wednesday after the company announced the roll out of ReadyStart...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
March 16, 2023
It's time for another dive into the biggest pre-market stock movers as we go over all the latest news for Thursday morning!
Via
InvestorPlace
The Latest Analyst Ratings for Esperion Therapeutics
February 27, 2023
Via
Benzinga
Looking Into Esperion Therapeutics's Return On Capital Employed
February 22, 2023
Via
Benzinga
Esperion Therapeutics's Earnings Outlook
February 20, 2023
Via
Benzinga
Recap: Esperion Therapeutics Q3 Earnings
November 01, 2022
Esperion Therapeutics (NASDAQ:ESPR) reported its Q3 earnings results on Tuesday, November 1, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
LivePerson, Amyris And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
March 16, 2023
U.S. stock futures traded mixed this morning. Here are some big stocks recording losses in today’s pre-market trading session.
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
March 15, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 7, 2023
March 07, 2023
Via
Benzinga
Esperion Therapeutics: Q2 Earnings Insights
August 02, 2022
Esperion Therapeutics (NASDAQ:ESPR) reported its Q2 earnings results on Tuesday, August 2, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
March 14, 2023
Tuesday's morning session saw 84 companies set new 52-week lows.
Via
Benzinga
DocuSign To Rally Around 25%? Here Are 10 Other Analyst Forecasts For Tuesday
March 07, 2023
Wells Fargo cut the price target for Cheniere Energy, Inc. (NYSE: LNG) from $236 to $230. Wells Fargo analyst Michael Blum maintained an Overweight rating. Cheniere Energy shares fell 4.8% to close at...
Via
Benzinga
Nasdaq Rises 50 Points; Ciena Earnings Top Expectations
March 06, 2023
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around 50 points on Monday. The Dow traded up 0.16% to 33,444.91 while the NASDAQ rose 0.43% to 11,739.11. The S&P...
Via
Benzinga
Why Aclaris Therapeutics Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session
March 06, 2023
Gainers Unicycive Therapeutics, Inc. (NASDAQ: UNCY) shares surged 159% to $1.27 after the company announced a private placement of up to $130 million in gross proceeds to commercialize and launch...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
March 06, 2023
Via
Benzinga
Dow Jumps Over 100 Points; BridgeBio Pharma Shares Spike Higher
March 06, 2023
U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 100 points on Monday. The Dow traded up 0.42% to 33,531.77 while the NASDAQ rose 0.97% to 11,802.73. The S&P 500...
Via
Benzinga
Nasdaq Rises 50 Points; US Factory Orders Down 1.6% In January
March 06, 2023
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining around 50 points on Monday. Following the market opening Monday, the Dow traded up 0.24% to 33,471.14 while the NASDAQ rose...
Via
Benzinga
Esperion Therapeutics Stock Is Diving: What's Going On?
March 06, 2023
Esperion Therapeutics Inc (NASDAQ: ESPR) shares are trading lower Monday after the company published new data on its treatment aimed at
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
March 06, 2023
Via
Benzinga
Why Hertz Global Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket
March 06, 2023
Gainers Secoo Holding Limited (NASDAQ: SECO) rose 44% to $1.44 in pre-market trading after dipping over 31% on Friday.
Via
Benzinga
Esperion Long Term Data On Cholesterol Medication's Ability To Cut Cardiovascular Risk Fails To Impress Investors
March 06, 2023
Via
Benzinga
Esperion Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session
March 06, 2023
U.S. stock futures traded mixed this morning. Here are some big stocks recording losses in today’s pre-market trading session.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2023
February 03, 2023
Via
Benzinga
Top Picks For 2023: Esperion
January 02, 2023
Esperion is a de-risked biotech company in the cardiovascular sector with its lead drug, bempedoic acid, already FDA approved to reduce LDL cholesterol. Let's take a closer look at why it's a top pick...
Via
Talk Markets
Esperion Therapeutics Reports Sooner Than Expected Positive Data From Nexletol Trial
December 07, 2022
Via
Benzinga
Esperion Therapeutics's Return On Capital Employed Insights
November 09, 2022
According to data from Benzinga Pro, during Q3, Esperion Therapeutics's (NASDAQ:ESPR) reported sales totaled $18.98 million. Despite a 16.9% increase in earnings, the company posted a loss of $55.12...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2022
August 03, 2022
Via
Benzinga
U.S. Stock Futures Gain Ahead of Services PMI; Crude Oil Drops Over 1%
August 03, 2022
Pre-open movers
Via
Benzinga
Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study
August 02, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.